HighPoint Advisor Group LLC Buys 395 Shares of IQVIA Holdings Inc. (NYSE:IQV)

HighPoint Advisor Group LLC raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 22.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,133 shares of the medical research company’s stock after acquiring an additional 395 shares during the quarter. HighPoint Advisor Group LLC’s holdings in IQVIA were worth $428,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Synergy Asset Management LLC bought a new stake in shares of IQVIA during the fourth quarter valued at approximately $33,000. Lee Danner & Bass Inc. purchased a new position in IQVIA during the fourth quarter valued at $44,000. Zions Bancorporation N.A. boosted its holdings in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after buying an additional 85 shares in the last quarter. Versant Capital Management Inc increased its stake in shares of IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after acquiring an additional 93 shares in the last quarter. Finally, SBI Securities Co. Ltd. purchased a new position in IQVIA during the 4th quarter valued at about $60,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

IQV has been the topic of a number of recent research reports. Royal Bank of Canada restated an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a report on Monday, February 10th. Stephens assumed coverage on IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target on the stock. Barclays lowered their price objective on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Finally, William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Stock Performance

IQV stock opened at $174.52 on Thursday. The company has a market cap of $30.77 billion, a P/E ratio of 23.27, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1 year low of $169.11 and a 1 year high of $252.88. The stock’s fifty day moving average price is $191.43 and its 200-day moving average price is $204.92.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.